BMEA BIOMEA FUSION INC

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Biomea Fusion Appoints Julianne Averill to its Board of Directors

SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board of Directors (the “Board”), effective July 22, 2025. Ms. Averill has also been appointed to serve as a member of the Audit Committee. She succeeds Bihua Chen, who has stepped down from the Board after more than four years of dedicated service.

“Julianne is an accomplished leader whose extensive financial, operational, and strategic expertise in the life sciences and digital health industries will be a tremendous asset to Biomea. Her proven track record in capital markets, governance, and healthcare innovation aligns with our mission to transform diabetes and obesity care. We look forward to Julianne’s contributions as we advance our programs and prepare for future growth,” said Mick Hitchcock, Interim Chief Executive Officer and member of the Board. “On behalf of the entire team and our Board, I would like to thank Bihua Chen for her many years of continued commitment to Biomea, her professional and expert guidance, and her ongoing support.”

Ms. Averill is a seasoned finance and strategy executive with over two decades of experience in high-growth life sciences and digital health companies across private, public, and global markets. She currently serves as Managing Director at Danforth Advisors, where she drives business growth on the West Coast and serves as interim Chief Financial Officer and strategic advisor to late-stage biopharma organizations. Her expertise spans capital markets, M&A, organizational design and operational scale, with direct involvement in transactions and strategic initiatives exceeding $10 billion in aggregate value.

Ms. Averill earned her B.S. in Business Administration and an M.S. in Accountancy, both from California State University. She is also a licensed CPA in California, is a Society of Human Resources Certified Professional, and holds the National Association of Corporate Directors Directorship Certification.

About Biomea Fusion

Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both being developed to significantly improve the lives of patients with diabetes, obesity, and metabolic diseases. We aim to cure.

 

Visit us at and follow us on , and . 

Contact:  

Meichiel Jennifer Weiss  

Sr. Director, Investor Relations and Corporate Development

  



EN
24/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOMEA FUSION INC

 PRESS RELEASE

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Biomea Fusion Appoints Julianne Averill to its Board of Directors SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board of Directors (the “Board”), effective July 22, 2025. Ms. Averill has also been appointed to serve as a member of the Audit Committee. She succeeds Bihua Chen, who has stepped down from the Board after more than four years of dedicated service. “Julianne is an accomplishe...

 PRESS RELEASE

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib...

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA) In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide aloneIcovamenib promoted healthy myotube morphology and diminished drug-induced atrophy in ex vivo 3D-engineered human myotube culturesIn severely insulin-deficient patients from the Phase II COVALENT-111 trial,...

 PRESS RELEASE

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation ...

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the second half of 2025; with Phase I study initiation in obese, otherwise healthy volunteers anticipated late 2025 REDWOOD CITY, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Biomea Fusio...

 PRESS RELEASE

Biomea Fusion Announces Pricing of Public Offering of Securities

Biomea Fusion Announces Pricing of Public Offering of Securities REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 19,450,000 shares of its common stock and accompanying warrants to purchase an aggregate of 19,450,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to ...

 PRESS RELEASE

Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion Announces Proposed Public Offering of Securities REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch